中国早产儿视网膜病变分类和治疗专家共识(2023年)

Expert consensus on the classification and treatment of retinopathy of prematurity in China(2023 edition)

早产儿视网膜病变(ROP)是新生儿致盲性眼病,早期筛查和定期随访可以预防该病导致严重视功能损害,被世界卫生组织归类为新生儿可避免盲的防治目标。自2004年中华人民共和国国家卫生健康委员会颁发《早产儿治疗用氧和视网膜病变防治指南》以来,中华医学会眼科学分会眼底病学组积极推动ROP的筛查和治疗,于2014年更新了《中国早产儿视网膜病变筛查指南》。经过近二十年的努力,我国5期ROP病变基本消失。为了合理掌握ROP分类标准及药物治疗的适应证,中华医学会眼科学分会眼底病学组、中国医师协会眼科医师分会眼底病专委会组织相关领域专家通过认真、全面、充分讨论达成共识性意见,参考国际标准术语更新了我国ROP的分类和新名词术语的中文译名,并补充制定抗血管内皮生长因子药物治疗适应证的标准,以供临床医师在临床实践中参考应用。

Retinopathy of prematurity(ROP)is a blinding eye disease of neonates.Early screening and regular follow-up can prevent the disease from leading to serious functional impairment.Rop is classified by the World Health Organization as the prevention target of avoidable blindness in neonates.Since the National Health Commission of the People's Republic of China issued"Guidelines for the treatment of oxygen and the prevention and treatment of retinopathy in prematurity"in 2004,the Ophthalmology Group of the Chinese Academy of Ophthalmology has actively promoted the screening and treatment of ROP,and updated"Guidelines for screening retinopathy of prematurity"in China in 2014.After nearly 20 years of hard work,the disease of stage 5 ROP in China has basically disappeared.In order to reasonably grasp the classification criteria of ROP and the indications of drug treatment,Fundus Disease Group of Ophthalmological Society of Chinese Medical Association,Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association organize experts in related fields to reach consensus opinions through serious,comprehensive and full discussion,and update the classification of ROP in China and the Chinese translation of new terms with reference to international standard terms.The standard of anti-vascular endothelial growth factor drug treatment indication is also added to provide reference for clinicians in clinical practice.